BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bioxyne (BXN) on Track to Report Clinical Trial Results in June


5/29/2012 9:32:25 AM

SYDNEY Australia 28 May 2012: Bioxyne Limited (ASX: BXN), today confirmed it is on track for the release of data from its Phase IIb trial as scheduled in June.

The Company confirmed the 320-patient study to evaluate the efficacy and safety of the Bioxyne’s HI-164OV therapy for patients with chronic obstructive pulmonary disease (COPD) had been closed and that data was in the late stages of analysis.

The primary aim of the study is to assess the impact of treatment with HI-164OV in reducing severe exacerbations in COPD patients and reducing the need for admission to hospital.

There are a number of measures of disease severity being examined which will define the profile and benefits of HI-164OV and its potential long term value.

Bioxyne Chief Executive Officer David Radford said, “We are focused on ensuring accurate communication of the trial results and to also guard against partial and incomplete reporting of the results.

“Given the importance of the results, Bioxyne may consider a short-term trading halt during the period between our receipt of initial data through until the time when the Company has formally assessed the final result and is able to accurately communicate these results to the market.

The primary endpoint in the trial is a demonstration of a reduction in exacerbations requiring oral corticosteroid treatment or hospitalisation.

The secondary endpoints seek to determine if HI-164OV can reduce the severity of exacerbations, the number of patients experiencing exacerbations requiring corticosteroid treatment or hospitalisation and a reduction in the use of antibiotics and or corticosteroids.

There have been no indications of patient related safety issues during the trial.

About Bioxyne

Bioxyne Limited (ASX: BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit www.bioxyne.com

At the Company

David Radford

Chief Executive Officer

Tel: +61 (0) 407-218-922

Email: info@bioxyne.com

Media contacts

College Hill

Sue Charles – (UK) +44 (0)7968 726585 (AUS) +61 (0)466 924218

Gemma Howe – (UK) +44 (0)20 7866 7860

Email: bioxyne@collegehill.com

City Public Relations

Tim Allerton or Andrew Geddes (AUS) +(02) 9267 4511



Read at BioSpace.com

Bioxyne
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES